Clinical Trial Update: Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study evaluating 161Tb-SibuDAB, a new PSMA-targeted radioligand therapy, in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 161Tb-SibuDAB (Terbium-161 labeled SibuDAB PSMA ligand)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Castration-resistant Prostate Cancer | Phase 1 | Status: RECRUITING